Long-term survival in patients with non-small cell lung cancer and synchronous brain metastasis treated with whole-brain radiotherapy and thoracic chemoradiation

Table 2 Series evaluating radiation therapy or chemoradiotherapy of lung cancer in NSCLC with brain metastasis

Study	Year	Number of patients	Number of brain metastases	Brain treatment	Median survival, months	1-year survival rate (%)	2-year survival rate (%)	5-year survival rate (%)	Prognostic factors
Chidel et al.[13]	1999	Sx = 2 Sx + RT = 3 RT = 8 Palliative = 15	1	Sx WBRT STS and combination	Overall: 6.9 Definitive tx: 20.1 No definitive tx: 3.5		12 (3-year)		WBRT Aggressive thoracic treatment
Moazami et al.[31]	2002	Chemo/RT = 29 Sx = 59	42 pts: 1 49 pts: > 1 Metachronous brain lesions	Sx WBRT STS and combinations	5.2	22	10	-	Younger age Stage IIIA Lung resection ECOG No extracranial mets Sx of brain mets STS
Hu et al.[17]	2006	RT = 44 Chemo = 23 Chemo/RT = 13	1	Sx STS	Overall: ~15 Stage I: 25.6 Stage II: 9.5 Stage III: 9.9	49.8	16.3	7.6	Thoracic stage I
Ampil et al.[26]	2007	> 65 year RT = 22 No RT = 50	1	WBRT STS Sx and combinations	RT = 5 No RT = 3 p = 0.28	RT = 14 No RT = 11 p= 0.28	-	-	Sx of brain mets
Flannery et al.[18]	2008	RT = 26 Chemo/RT = 9 Sx = 12 Preop Chemo + Sx = 5	1	STS	Overall: 18 Definitive tx: 26.4 No definitive tx: 13.1 p < 0.0001	Overall: 71.3	Overall: 34.1	Overall: 21 RT: 34.6 No RT: 0 p < 0.0001	Definitive thoracic therapy KPS
Louie et al.[16]	2009	Sx = 8 Chemo = 24 RT = 14	1	Sx + WBRT	7.8 Stage I/II: 14.7 Stage III: 7	-	-	-	Lung surgery^a Primary lung treatment^a > 8 weeks after brain Sx^a Stage I/II disease^a
Arrieta et al. (present series)	2010	Chemo-Chemo/RT = 30	> 1	WBRT	31.8	71.1	60.2		3-year OS for N0-1 was 60 vs. 24% for N2-3

NSCLC: Non-small-cell lung cancer; Sx: Surgery; RT: Radiotherapy; WBRT: Whole-brain radiotherapy; STS: Stereotactic surgery; Comb: Combination; Mets: Metastasis/Metastases; Chemo: Chemotherapy; Chemo/RT: Chemo-radiotherapy; Preop: Pre-operative. a) Univariate analysis.